OncoGenex: A Cancer Biotech Worth Betting On

In the next few weeks I plan to highlight under-appreciated and under-followed biotech companies-the first of which is OncoGenex (NASDAQ:OGXI). These names represent a significant profit potential for those who have a longer-term perspective. Too many traders have a very short hold period and, in turn, miss opportunities that Endocyte (NASDAQ:ECYT) or Pharmacyclics (NASDAQ:PCYC) can give their portfolio over a period of 1-3 years.

As the first installment in this series of CEO interviews, I would like to introduce OncoGenex CEO Scott Cormack and show how he has built a unique cancer biotechnology company. This exclusive interview with Mr. Cormack makes a case that OncoGenex is a bargain-buy at today's price levels.

OncoGenex is...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details